Date: 2017-07-05
Type of
information: Publication of results in a medical journal
phase:
Announcement: publication of results in Nature
Company:
Product:
Action
mechanism:
Disease:
Therapeutic
area:
Country:
Trial
details:
Latest
news:
- • On July 5, 2017, Neon Therapeutics, an immuno-oncology company developing neoantigen-based therapeutic vaccines and T cell therapies to treat cancer, announced the publication of an article in Nature presenting initial feasibility, safety, immunogenicity and clinical outcomes for a personalized neoantigen vaccine in patients with adjuvant melanoma. The article entitled ‘An immunogenic personal neoantigen vaccine for patients with melanoma’ demonstrates the validity of the neoantigen vaccine approach as an effective immunotherapy. Senior author is Catherine Wu, MD, Associate Professor at the Dana-Farber Cancer
Institute and Neon Therapeutics founder, working closely with Nir Hacohen, PhD, Institute Member at the Broad Institute, Director of Cancer Immunology at Massachusetts
General Hospital and Neon Therapeutics founder, and Ed Fritsch, PhD, now Chief Technology Officer and founder at Neon Therapeutics.
- Lead authors are Patrick Ott, MD PhD, Assistant Professor of Medicine, and Zhuting Hu, PhD, post-doctoral fellow at the
Dana-Farber Cancer Institute.
Is
general: Yes
